Major Drivers Propelling the Growth oh theMetabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Forward: Rising Obesity Prevalence Driving Growth In The Market
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Is the Current and Projected Market Size of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Through 2034?
The market size for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) has seen a surge in growth recently. The market is projected to rise from $2.00 billion in 2024 to $2.60 billion in 2025, showcasing a compound annual growth rate (CAGR) of 30.0%. The notable growth in the past was majorly influenced by the increasing number of cases of non-alcoholic steatohepatitis, contemporary dietary habits, consumption of processed foods, sedentary living conditions, and greater occurrence of metabolic conditions.
The market size for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) is projected to experience rapid growth in the coming years, expanding to a value of $7.38 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 29.8%. Factors contributing to this predicted growth from the forecast period include the rising incidence of obesity and related diseases, timely medical intervention, reimbursement policies, insurance provisions, and heightened awareness about liver diseases. Key trends observed in the forecast period encompass enhancements in technology, pipeline development, strategic alliances and partnerships, individualized medicine, precision therapies, and willingness for investment in research activities and clinical trials.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The escalating instances of obesity are projected to propel the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market. Obesity, a health condition defined by excessive body fat that could potentially harm general wellness, is ordinarily calculated by a body mass index (BMI) of 30 or above. The global upsurge in obesity is influenced by inactive daily routines, unhealthy eating habits, and metabolic risk elements. The treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in obesity aims at managing insulin resistance, diminishing liver fat, and enhancing metabolic health via lifestyle modifications and specified therapies. For example, the World Heart Foundation, a Swiss-based non-government global cardiovascular community, reported in March 2023 that currently about 2.3 billion adults and children worldwide are either overweight or obese. With the ongoing trend of obesity, this statistic is expected to grow to 2.7 billion by 2025. Hence, the rising instances of obesity are contributing to the growth of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
Which Key Market Segments Comprise the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market and Drive Its Revenue Growth?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Which Areas Are Leading Regions in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Expansion Across the Globe?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Leading firms in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are shifting their attention towards creating inventive products, such as liver fibrosis treatment options, to cater to the needs of patients suffering from MASH and moderate to severe liver fibrosis. These treatments are designed to tackle the root cause of liver damage, including lifestyle corrections, antiviral drugs, and innovative antifibrotic treatments, with the ultimate goal of stopping or reversing the advancement of fibrosis to enhance liver function. For example, in March 2024, Madrigal Pharmaceuticals, Inc., a biopharmaceutical business based in the United States, reported that the FDA approved Rezdiffra (resmetirom), the pioneer treatment for MASH with moderate to severe liver fibrosis. Rezdiffra, an everyday oral tablet, showed effectiveness in addressing MASH without exacerbating fibrosis and improved liver fibrosis in Phase 3 clinical trials. This significant development introduces a non-invasive therapeutic alternative, eliminating the requirement for liver biopsies, and greatly enhances patient convenience and results in managing fatty liver disease.
View the full report here:
How Is the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Conceptually Defined?
Metabolic dysfunction-associated steatohepatitis (MASH) treatment refers to medical and lifestyle interventions aimed at addressing inflammation and liver damage caused by fat accumulation in the liver associated with metabolic dysfunctions like obesity, diabetes, and insulin resistance, focusing on improving liver health and metabolic outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
